Vitamin B12a safety check: first step toward new gut disease treatments?
NCT ID NCT07469189
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 study gave hydroxocobalamin (a form of vitamin B12a) to 10 healthy adults to see how well it is tolerated. The goal was to gather safety and symptom data before testing the drug in people with ulcerative colitis, primary sclerosing cholangitis, or pouchitis. Researchers monitored stool consistency, frequency, and other GI symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- hydroxocobalamin (vitamin B12a)
- What this could lead to
- If this initial safety study succeeds, it could pave the way for testing hydroxocobalamin as a treatment for ulcerative colitis, primary sclerosing cholangitis, and pouchitis.
- What could go wrong
- This is a very early Phase 1 study with only 10 healthy participants, so results may not predict effectiveness in patients with GI diseases. The drug is being repurposed, and its safety for these new uses is not yet known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYDROXOCOBALAMIN ADVERSE REACTION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States